Trial Profile

A Phase I Study to Evaluate the Safety and Efficacy of RP72 Monotherapy and in Combination With Gemcitabine in Patients With Pancreatic Cancer

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 01 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gemcitabine (Primary) ; RP 72 (Primary)
Indications Pancreatic cancer
Focus Adverse reactions
Sponsors Rise Biopharmaceuticals

Most Recent Events

27 Mar 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2025.
27 Mar 2023 Planned primary completion date changed from 31 Oct 2022 to 31 Oct 2024.
07 May 2021 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com